Merck makes haste to catch up in KRAS
The company is setting up another battle with Bristol Myers Squibb, while Amgen has different plans.
FDA green and red lights: Q1 2024
A roundup of the first quarter's key oncology drug approvals and rejections.
Immutep approaches Lag3 crunch time
Results with eftilagimod alpha in first-line head and neck cancer threaten to cloud partnering prospects.
Yervoy delivers a surprise in liver cancer
Checkmate-9DW scores a topline win on overall survival, when failure seemed more likely.
Merck matches Kelun’s saci-tirumo efforts
Three recently added trials take Merck & Co’s tally of phase 3 sacituzumab tirumotecan studies to six.
